All proteins were further purified by anion exchange chromatography on a Q-sepharose column (GE Healthcare Life Sciences) in 25 mM Tris, pH 8.0 eluting over a gradient from 0.05-1 M NaCl over 7 column volumes. Under these buffer conditions, ALIX Bro1 does not bind to the Q sepharose column, whereas ALIX Bro1-V binds and is eluted during the NaCl gradient. ALIX protein-containing fractions were pooled, concentrated and further purified by size exclusion chromatography using a Superdex 75 column (GE) ALIX Bro1: 10 mM Tris, pH 8.0, 100 mM NaCl, 1 mM DTT) or a Superdex 200 column (GE) (ALIX Bro1-V: 20 mM sodium phosphate, pH 7.2, 150 mM NaCl, 5 mM BME). Pure ALIX protein-containing fractions were pooled, concentrated and used for binding or crystallographic studies. Typical yields were 8-10 mg/L culture (ALIX Bro1-V), and 15-20 mg/L culture (ALIX Bro1).
GST pull-down assay:
GST-fused CHMP4C peptides spanning the ALIX binding helix (residues 216-233) from CHMP4C A232 or the CHMP4C L228A,W231A or CHMP4C T232 mutants were expressed in BL21 E. coli by IPTG induction (0.5 mM) for 4 hours at 37°C. Cells were harvested, resuspended in bacterial lysis buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA), Protease Inhibitor Cocktail (Roche), and Lysozyme (1 mg/mL) and sonicated. Lysates were clarified by centrifugation at 28,000 x g for 30 minutes, proteins were immobilized on glutathione-Sepharose 4ß resin, and unbound protein was removed by repeated washes in 50 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA. Bound protein quantities were determined by SDS-PAGE and Coomassie staining. Equal protein quantities of GST or GST-CHMP4C fusions bound to glutathione-Sepharose were incubated with 1 ml of 1 mg/ml clarified HeLa cell lysate for 3 hours with rotation at 4°C in binding buffer: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5% glycerol, 1% Triton X-100. HeLa cells were grown as described, lysed in binding buffer by sonication, clarified by centrifugation and protein content was determined using microBCA kit (Thermo Scientific). Following incubation with GST-CHMP4C fusion proteins, unbound proteins were removed by four washes with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5% glycerol, 0.1% Triton X-100. Bound proteins were eluted with Laemelli sample buffer and analyzed by SDS-PAGE followed by immunoblotting or Coomassie staining.
Yeast two-hybrid assay:
Yeast two-hybrid assays were carried out as described previously (4) . Briefly, full-length CHMP4C proteins were fused to the VP16 activation domain (pHB18) and full-length binding partners (ALIX or CHMP4C) were fused to Gal4 DNA binding domain (pGBKT7). Yeast Y190 cells were co-transformed with plasmids and grown under selection with SD-Leu-Trp for 3 days at 30°C. Cells were harvested and LacZ activity was measured with a liquid β -galactosidase assay using chlorophenol-red-β-Dgalactopyranoside (Roche) as a substrate.
CRISPR deletion of the CHMP4C locus:
CRISPR guides targeting the CHMP4C gene immediately prior to the start and following the stop codon were designed using http://crispr.mit.edu/ (5). Guide RNA sequences were TCGGAGGGCCAGCGATCCCG and TGCATACATAGAATCAGTGA. These were cloned into a Cas9 containing GFP lentiviral packaging vector (pLG2C). Target HCT116 cell lines were co-transfected with both guides for 48 hours. Single cells expressing vectors were isolated by fluorescence-activated cell sorting based on GFP fluorescence and cultured until ready for screening. The CHMP4C status of CRISPR-treated clones was determined at the mRNA level using Qiagen RNeasy kit followed by cDNA synthesis (Applied Biosystems), and PCR. The CHMP4C status of clones was also determined at the genomic level using DNeasy Blood and Tissue kit (Qiagen) followed by PCR. Primers used in this study are available in Table S2 . Protein expression was determined by immunoblotting (Fig. S3) . Immunoblots showing siRNA efficiency. (E) Cells were categorised based on their nuclear morphology, shown are meanSD, n>900 cells, from 3 independent experiments. P-value calculated using 2-way ANOVA and Sidak's multiple comparisons test comparing each category to siNT, ***P<0.001. WT or HCT116 CHMP4C cells. Shown are representative data from one of 4 independent experiments. Data were collected from >100 cells, mean value is marked, Pvalues calculated using one-way ANOVA,***P<0.001. (C) Representative immunofluorescence images from (B), stained with 53BP1 (green) and DNA (DAPI, blue). Scale bars are 20 µm. Figs. 2, 3, 4 , S1, S2, S3, S4, S6, S8 and S9. Movies S13-S15. CHMP4C is not involved in mitotic nuclear envelope reformation. Movies of stills shown in Fig. S4A . Cells stably expressing GFP-NLS and H2B-mCherry were treated with non-targeting (Movie S13), CHMP7 (Movie S14) or CHMP4C (Movie S15) siRNA, subjected to time-lapse microscopy and were imaged and nuclear GFP-NLS fluorescence intensity relative to cytoplasmic fluorescence intensity was determined with ImageJ. Related to Fig. S4 .
Fig S10. Unprocessed/full scans of immunoblots presented in
Movies S16-S19. Reversine induces anaphase chromosome segregation errors. Cells stably expressing H2B-mCherry were treated with DMSO (Movies S16, S17) or 0.1 M reversine (Movies S18, S19) and cell division events were followed by time-lapse microscopy. Cells were scored for anaphase defects (marked with arrowhead). Movies S16, S18 show anaphases with no defects, whereas Movies S17, S19 show defective anaphases. Related to Fig S7B. Movies S20-S23. p53 depletion induces anaphase chromosome segregation errors. Cells stably expressing H2B-mChery and either control shRNA (shCtrl, Movies S20, S21) or shRNA against p53 (shp53, Movies S22, S23) were followed by time-lapse microscopy and cells were scored for anaphase defects (marked with arrowheads). Movies S20, S22 show anaphases with no defects, whereas Movies S21, S23 show defective anaphases. Related to Fig S7C. 
